Table 2.
The evolution of ESR, CRP and DAS 28 for 12 months based on the average (Mean ± SD)
| Infliximab | Etanercept | Adalimumab | Rituximab | |
| Nr | 25 | 34 | 18 | 91 |
| VSH_init | 33,08 ± 18,12 | 32,59 ± 18,07 | 48,67 ± 22,96 | 33,80 ± 14,66 |
| VSH_6l | 16.68±6.19 | 16.32±6.98 | 21.89±9.32 | 18.10±7.72 |
| VSH_12l | 9.76±4.10 | 9.82±4.45 | 11.50±3.65 | 10.85±5.53 |
| CRP_init | 11.44±10.69 | 10.25±+5.64 | 23.36±23.94 | 17.00±16.00 |
| CRP_6l | 5.92±6.16 | 4.85±2.48 | 10.33±11.00 | 8.63±8.23 |
| CRP_12l | 2.68±2.72 | 2.19±1.53 | 3.34+1.68 | 4.66±4.42 |
| DAS28_init | 5.72±0.32 | 5.72±0.40 | 5.69±0.44 | 5.60±0.30 |
| DAS28_6l | 3.61±0.28 | 3.70±0.41 | 3.85±0.73 | 3.27±0.37 |
| DAS28_12l | 2.35±0.33 | 1.97±0.53 | 2.35±0.73 | 2.08±0.61 |